Viracta Therapeutics Accounts Payable

Viracta Therapeutics (VIRX) currently reports a accounts payable of $1.8M as of September 2024. That compares with $2.4M in the prior-year period — down 23.1% year over year. Use the charts on this page to explore Viracta Therapeutics's accounts payable history and peer comparisons.

Viracta Therapeutics's accounts payable decreased from $2.4M to $1.8M — a 23.1% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Viracta Therapeutics reported $1.8M in accounts payable as of September 2024. That compares with $2.4M in the prior-year period — down 23.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $1.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Viracta Therapeutics, and consider following VIRX for alerts when major investors trade the stock.

Viracta Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $1.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VIRX with unrelated industries.